2 Pyrroloquinoline quinone improves brain function in both younger and older adults 3 Pyrroloquinoline quinone alleviates natural aging-related osteoporosis 4 Glutathione and glutathione-dependent enzymes: From biochemistry to gerontology and successful aging A photo accompanying this announcement is available at
In the PIONEER program, the mean treatment adherence of patients who received oral semaglutide 14 mg, liraglutide 1.8 mg, empagliflozin 25 mg, sitagliptin 100 mg and placebo were 82.6% (79.686.3%), 83.7%, 89.0%, 88.9% (86.990.8%), and 88.8% (87.690.1%) respectively [39,40,41,42,43,44,45,46]
A meaningful reduction in intracranial pressure has been reported at all time points in the exenatide group as compared to the placebo group
Third global licensing deal for GMRx2 (following agreements in the US, Canada, Mexico, Colombia & Central America)
Assists in healthy wei